Nurix Therapeutics’ (NRIX) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Nurix Therapeutics (NASDAQ:NRIX) in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a $26.00 target price on the stock.

A number of other equities research analysts have also recently issued reports on the company. Mizuho upped their price objective on Nurix Therapeutics from $24.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. Piper Sandler upped their price objective on Nurix Therapeutics from $32.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday, January 29th. Royal Bank Of Canada upped their price objective on Nurix Therapeutics from $28.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, January 29th. Morgan Stanley set a $36.00 price objective on Nurix Therapeutics and gave the stock an “overweight” rating in a research note on Thursday, January 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.54.

Nurix Therapeutics Stock Down 4.6%

NASDAQ:NRIX opened at $15.60 on Wednesday. Nurix Therapeutics has a twelve month low of $8.18 and a twelve month high of $22.50. The business has a 50 day moving average price of $15.72 and a two-hundred day moving average price of $15.22. The company has a market cap of $1.61 billion, a P/E ratio of -5.13 and a beta of 1.97.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Tuesday, April 14th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). Nurix Therapeutics had a negative return on equity of 57.51% and a negative net margin of 314.90%.The firm had revenue of $6.25 million for the quarter, compared to analyst estimates of $14.25 million. As a group, analysts anticipate that Nurix Therapeutics will post -2.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,661 shares of the stock in a transaction on Friday, January 30th. The stock was sold at an average price of $16.60, for a total transaction of $60,772.60. Following the transaction, the chief financial officer owned 45,427 shares in the company, valued at $754,088.20. This trade represents a 7.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gwenn Hansen sold 4,895 shares of the stock in a transaction on Friday, January 30th. The stock was sold at an average price of $16.60, for a total value of $81,257.00. Following the transaction, the insider owned 83,672 shares in the company, valued at $1,388,955.20. The trade was a 5.53% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Larson Financial Group LLC increased its position in Nurix Therapeutics by 339.0% during the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after buying an additional 1,190 shares during the period. Intesa Sanpaolo Wealth Management acquired a new stake in shares of Nurix Therapeutics during the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Nurix Therapeutics during the 4th quarter worth $33,000. Wexford Capital LP acquired a new stake in shares of Nurix Therapeutics during the 3rd quarter worth $41,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Nurix Therapeutics by 118.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock worth $73,000 after purchasing an additional 3,475 shares in the last quarter.

Nurix Therapeutics News Summary

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix advanced NX-5948 into a Phase 3, randomized head‑to‑head study in CLL/SLL — a de‑risking step for a leading oral degrader and a clear potential long‑term value driver if the program reads out well. Nurix Advances NX-5948 Into Phase 3 Head-to-Head Battle in CLL/SLL
• Positive Sentiment: Nurix is enrolling the Phase 2 DAYBreak CLL‑201 bexobrutideg trial intended to support accelerated approval in relapsed/refractory CLL — this could create nearer‑term regulatory and commercial optionality if the data are strong. Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
• Positive Sentiment: Needham reaffirmed a Buy rating with a $26 price target (~66% above current levels), which may support investor demand if confidence in the clinical pipeline persists. Benzinga Coverage of Needham Rating
• Neutral Sentiment: Company to present at an upcoming investor conference — provides management a forum to update analysts and investors but is unlikely to move the stock unless new data or guidance are announced. Nurix Therapeutics to Participate in Upcoming Investor Conference
• Neutral Sentiment: Some headlines noted the stock briefly edged higher despite the Q1 miss, reflecting mixed intraday positioning and interest from buyers focused on clinical catalysts. Nurix Therapeutics shares edge higher despite Q1 earnings miss
• Negative Sentiment: Q1 results missed expectations: GAAP loss of $0.79/sh vs. consensus ‑$0.76, revenue $6.25M well below $14.25M expected — signaling heavier near‑term cash burn and raising skepticism about short‑term revenue traction. Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates
• Negative Sentiment: Analysts and coverage highlighted expanding losses and increased R&D investment, which could pressure the share price until clinical readouts or partnerships validate the spending. Nurix Therapeutics (NRIX) Stock Declines Amid Expanding Losses and R&D Investment

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.